Regulation of alternative polyadenylation by Nkx2-5 and Xrn2 during mouse heart development

  1. Keisuke Nimura  Is a corresponding author
  2. Masamichi Yamamoto
  3. Makiko Takeichi
  4. Kotaro Saga
  5. Katsuyoshi Takaoka
  6. Norihiko Kawamura
  7. Hirohisa Nitta
  8. Hiromichi Nagano
  9. Saki Ishino
  10. Tatsuya Tanaka
  11. Robert J Schwartz
  12. Hiroyuki Aburatani
  13. Yasufumi Kaneda
  1. Osaka University Graduate School of Medicine, Japan
  2. Kyoto University Graduate School of Medicine, Japan
  3. Osaka University, Japan
  4. University of Houston, United States
  5. The University of Tokyo, Japan

Abstract

Transcription factors organize gene expression profiles by regulating promoter activity. However, the role of transcription factors after transcription initiation is poorly understood. Here, we show that the homeoprotein Nkx2-5 and the 5'-3' exonuclease Xrn2 are involved in the regulation of alternative polyadenylation (APA) during mouse heart development. Nkx2-5 occupied not only the transcription start sites (TSSs) but also the downstream regions of genes, serving to connect these regions in primary embryonic cardiomyocytes (eCMs). Nkx2-5 deficiency affected Xrn2 binding to target loci and resulted in increases in RNA polymerase II (RNAPII) occupancy and in the expression of mRNAs with long 3'untranslated regions (3' UTRs) from genes related to heart development. siRNA-mediated suppression of Nkx2-5 and Xrn2 led to heart looping anomaly. Moreover, Nkx2-5 genetically interacts with Xrn2 because Nkx2-5+/-Xrn2+/-, but neither Nkx2-5+/- nor Xrn2+/-, newborns exhibited a defect in ventricular septum formation, suggesting that the association between Nkx2-5 and Xrn2 is essential for heart development. Our results indicate that Nkx2-5 regulates not only the initiation but also the usage of poly(A) sites during heart development. Our findings suggest that tissue-specific transcription factors is involved in the regulation of APA.

Article and author information

Author details

  1. Keisuke Nimura

    Division of Gene Therapy Science, Osaka University Graduate School of Medicine, Suita, Japan
    For correspondence
    nimura@gts.med.osaka-u.ac.jp
    Competing interests
    The authors declare that no competing interests exist.
  2. Masamichi Yamamoto

    Department of Nephrology, Kyoto University Graduate School of Medicine, Kyoto, Japan
    Competing interests
    The authors declare that no competing interests exist.
  3. Makiko Takeichi

    Division of Gene Therapy Science, Osaka University Graduate School of Medicine, Suita, Japan
    Competing interests
    The authors declare that no competing interests exist.
  4. Kotaro Saga

    Division of Gene Therapy Science, Osaka University Graduate School of Medicine, Suita, Japan
    Competing interests
    The authors declare that no competing interests exist.
  5. Katsuyoshi Takaoka

    Developmental Genetics Group, Osaka University, Suita, Japan
    Competing interests
    The authors declare that no competing interests exist.
  6. Norihiko Kawamura

    Division of Gene Therapy Science, Osaka University Graduate School of Medicine, Suita, Japan
    Competing interests
    The authors declare that no competing interests exist.
  7. Hirohisa Nitta

    Division of Gene Therapy Science, Osaka University Graduate School of Medicine, Suita, Japan
    Competing interests
    The authors declare that no competing interests exist.
  8. Hiromichi Nagano

    Division of Gene Therapy Science, Osaka University Graduate School of Medicine, Suita, Japan
    Competing interests
    The authors declare that no competing interests exist.
  9. Saki Ishino

    Center for Medical Research and Education, Osaka University Graduate School of Medicine, Suita, Japan
    Competing interests
    The authors declare that no competing interests exist.
  10. Tatsuya Tanaka

    Center for Medical Research and Education, Osaka University Graduate School of Medicine, Suita, Japan
    Competing interests
    The authors declare that no competing interests exist.
  11. Robert J Schwartz

    Department of Biology and Biochemistry, University of Houston, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Hiroyuki Aburatani

    Genome Science Division, The University of Tokyo, Tokyo, Japan
    Competing interests
    The authors declare that no competing interests exist.
  13. Yasufumi Kaneda

    Division of Gene Therapy Science, Osaka University Graduate School of Medicine, Suita, Japan
    Competing interests
    The authors declare that no competing interests exist.

Ethics

Animal experimentation: The protocols (3422-1 and 24-084-012) are approved by the Ethics Committee for Animal Experiments of the Osaka University Graduate School of Medicine.with protocols

Copyright

© 2016, Nimura et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,261
    views
  • 571
    downloads
  • 20
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Keisuke Nimura
  2. Masamichi Yamamoto
  3. Makiko Takeichi
  4. Kotaro Saga
  5. Katsuyoshi Takaoka
  6. Norihiko Kawamura
  7. Hirohisa Nitta
  8. Hiromichi Nagano
  9. Saki Ishino
  10. Tatsuya Tanaka
  11. Robert J Schwartz
  12. Hiroyuki Aburatani
  13. Yasufumi Kaneda
(2016)
Regulation of alternative polyadenylation by Nkx2-5 and Xrn2 during mouse heart development
eLife 5:e16030.
https://doi.org/10.7554/eLife.16030

Share this article

https://doi.org/10.7554/eLife.16030

Further reading

    1. Chromosomes and Gene Expression
    2. Neuroscience
    Robyn D Moir, Emilio Merheb ... Ian M Willis
    Research Article

    Pathogenic variants in subunits of RNA polymerase (Pol) III cause a spectrum of Polr3-related neurodegenerative diseases including 4H leukodystrophy. Disease onset occurs from infancy to early adulthood and is associated with a variable range and severity of neurological and non-neurological features. The molecular basis of Polr3-related disease pathogenesis is unknown. We developed a postnatal whole-body mouse model expressing pathogenic Polr3a mutations to examine the molecular mechanisms by which reduced Pol III transcription results primarily in central nervous system phenotypes. Polr3a mutant mice exhibit behavioral deficits, cerebral pathology and exocrine pancreatic atrophy. Transcriptome and immunohistochemistry analyses of cerebra during disease progression show a reduction in most Pol III transcripts, induction of innate immune and integrated stress responses and cell-type-specific gene expression changes reflecting neuron and oligodendrocyte loss and microglial activation. Earlier in the disease when integrated stress and innate immune responses are minimally induced, mature tRNA sequencing revealed a global reduction in tRNA levels and an altered tRNA profile but no changes in other Pol III transcripts. Thus, changes in the size and/or composition of the tRNA pool have a causal role in disease initiation. Our findings reveal different tissue- and brain region-specific sensitivities to a defect in Pol III transcription.

    1. Biochemistry and Chemical Biology
    2. Chromosomes and Gene Expression
    Ting-Wen Chen, Hsiao-Wei Liao ... Chung-Te Chang
    Research Article

    The mRNA 5'-cap structure removal by the decapping enzyme DCP2 is a critical step in gene regulation. While DCP2 is the catalytic subunit in the decapping complex, its activity is strongly enhanced by multiple factors, particularly DCP1, which is the major activator in yeast. However, the precise role of DCP1 in metazoans has yet to be fully elucidated. Moreover, in humans, the specific biological functions of the two DCP1 paralogs, DCP1a and DCP1b, remain largely unknown. To investigate the role of human DCP1, we generated cell lines that were deficient in DCP1a, DCP1b, or both to evaluate the importance of DCP1 in the decapping machinery. Our results highlight the importance of human DCP1 in decapping process and show that the EVH1 domain of DCP1 enhances the mRNA-binding affinity of DCP2. Transcriptome and metabolome analyses outline the distinct functions of DCP1a and DCP1b in human cells, regulating specific endogenous mRNA targets and biological processes. Overall, our findings provide insights into the molecular mechanism of human DCP1 in mRNA decapping and shed light on the distinct functions of its paralogs.